glp-1 gastroparesis legal team in michigan While many patients are seeing life-changing results with medications, doctors say the medications can also come with risks if they are not dosed properly: https://www.wkrg.com/news/experts-warn-of-dosing-issues-with-glp-1-weight-loss-drugs Reality Check: Doctors Challenge GLP-1

Clinical trials (ten studies, 419 participants) using doses from 400 mg to 10 g over 21 days to 20 months show consistent reductions in fasting glucose, post-meal glucose, and HbA1c. In diabetic animal studies, gymnema increased proglucagon gene expression (a precursor for GLP-1) and insulin gene activity, suggesting it may help amplify endogenous GLP-1 production

Phase I clinical trial results for Amgens experimental weight-loss drug, MariTide, indicate it may provide longer-lasting effects compared to existing glucagon-like peptide-1 (GLP-1) treatments such as Novo Nordisks Wegovy and EliLillys Zepbound.

High fill rates of GLP-1 receptor agonist prescriptions in those with mood disorders could indicate that multimorbidity begets more treatment.

This alert explains FDAs concerns, the misbranding theories at issue, and key compliance considerations for telehealth, compounding, and life sciences companies.